ALSO READZydus receives final approval for Oxybutynin Chloride Extended-Release Tablets Zydus Cadila receives final approval for Memantine Hydrochloride Tablets Zydus receives final approval for Temozolomide Capsules Zydus receives final approval for Phentermine Hydrochloride Orally Disintegrating Tablets Zydus Cadila receives final approval for Cyproheptadine Hydrochloride Tablets USP
From USFDAZydus Cadila has received the final approval from the USFDA to market Diltiazem Hydrochloride Extended-Release Capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain) and certain heart rhythm disorders. It will produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)